JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.21B |
| 2 |
Arthur J. Gallagher & Co
AJG
|
+$2.24B |
| 3 |
Walt Disney
DIS
|
+$2.18B |
| 4 |
Walmart Inc
WMT
|
+$1.96B |
| 5 |
McDonald's
MCD
|
+$1.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$2.77B |
| 2 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$2.64B |
| 3 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$2.5B |
| 4 |
iShares Broad USD High Yield Corporate Bond ETF
USHY
|
+$2.23B |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.61% |
| 2 | Technology | 23.17% |
| 3 | Financials | 10.12% |
| 4 | Consumer Discretionary | 9.84% |
| 5 | Healthcare | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5326
First Trust Mid Cap Growth AlphaDEX Fund
FNY
$574M
| $172K | ﹤0.01% |
2,153
-881
| -29% | -$73K |
2022 Q4
8 quarters
|
|
5327
Ramaco Resources Class B
METCB
$273M
| $172K | ﹤0.01% |
18,818
+8,547
| +83% | +$80.9K |
2023 Q2
6 quarters
|
|
5328
CALL
Toast
TOST
$17.4B
| $171K | ﹤0.01% |
+4,700
| New | +$165K |
2024 Q4
0 quarters
|
|
5329
Vanguard Short-Term Tax-Exempt Bond ETF
VTES
$2.37B
| $171K | ﹤0.01% |
1,705
-39,490
| -96% | -$3.98M |
2024 Q2
2 quarters
|
|
5330
Telomir Pharmaceuticals
TELO
$82.5M
| $171K | ﹤0.01% |
41,444
+37,980
| +1,096% | +$179K |
2024 Q1
3 quarters
|
|
|
SKYT
5331
DELISTED
SkyWater Technology
SKYT
| $170K | ﹤0.01% |
12,349
+292
| +2% | +$2.9K |
2021 Q2
14 quarters
|
|
5332
Immersion
IMMR
$246M
| $170K | ﹤0.01% |
19,509
+608
| +3% | +$5.31K |
2017 Q4
28 quarters
|
|
|
XHYD
5333
DELISTED
BondBloxx USD High Yield Bond Consumer Non-Cyclicals Sector ETF
XHYD
| $170K | ﹤0.01% |
4,522
-5,624
| -55% | -$214K |
2024 Q2
2 quarters
|
|
|
PARA
5334
CALL
DELISTED
Paramount Global Class B
PARA
| $169K | ﹤0.01% |
16,200
| – | – |
2022 Q1
11 quarters
|
|
5335
Innovator US Equity Power Buffer ETF February
PFEB
$902M
| $169K | ﹤0.01% |
+4,589
| New | +$167K |
2024 Q4
0 quarters
|
|
|
MBX
5336
MBX Biosciences
MBX
$2.81B
| $168K | ﹤0.01% |
+9,106
| New | +$194K |
2024 Q4
0 quarters
|
|
5337
Kingstone Companies
KINS
$267M
| $168K | ﹤0.01% |
11,042
+823
| +8% | +$10.4K |
2023 Q3
5 quarters
|
|
5338
CALL
Mobileye
MBLY
$6.19B
| $167K | ﹤0.01% |
8,400
| – | – |
2023 Q3
5 quarters
|
|
5339
Monte Rosa Therapeutics
GLUE
$882M
| $167K | ﹤0.01% |
24,094
+5,551
| +30% | +$41.7K |
2021 Q3
13 quarters
|
|
5340
ProShares Short QQQ
PSQ
$583M
| $167K | ﹤0.01% |
4,459
+1,713
| +62% | +$65.6K |
2022 Q3
9 quarters
|
|
5341
Invesco S&P International Developed Momentum ETF
IDMO
$4.3B
| $166K | ﹤0.01% |
+4,095
| New | +$171K |
2024 Q4
0 quarters
|
|
5342
Veru
VERU
$42.6M
| $166K | ﹤0.01% |
25,578
+19,730
| +337% | +$146K |
2018 Q1
27 quarters
|
|
5343
Century Therapeutics
IPSC
$268M
| $165K | ﹤0.01% |
163,189
+91,468
| +128% | +$125K |
2021 Q3
13 quarters
|
|
5344
First Trust Mid Cap Core AlphaDEX Fund
FNX
$1.32B
| $165K | ﹤0.01% |
1,424
+494
| +53% | +$59.1K |
2022 Q4
8 quarters
|
|
5345
SIGA Technologies
SIGA
$243M
| $164K | ﹤0.01% |
27,298
-43,001
| -61% | -$287K |
2018 Q1
27 quarters
|
|
5346
iShares iBonds 2027 Term High Yield and Income ETF
IBHG
$532M
| $164K | ﹤0.01% |
7,356
+2,125
| +41% | +$47.6K |
2024 Q2
2 quarters
|
|
5347
Saratoga Investment
SAR
$265M
| $162K | ﹤0.01% |
6,789
+1,789
| +36% | +$43.4K |
2024 Q3
1 quarter
|
|
5348
Franklin International Low Volatility High Dividend Index ETF
LVHI
$5.85B
| $162K | ﹤0.01% |
5,308
-96,904
| -95% | -$3M |
2023 Q2
6 quarters
|
|
5349
Lightwave Logic
LWLG
$888M
| $161K | ﹤0.01% |
76,795
-25,187
| -25% | -$72.2K |
2021 Q4
12 quarters
|
|
5350
WisdomTree Emerging Markets Local Debt Fund
ELD
$136M
| $161K | ﹤0.01% |
6,348
+2,937
| +86% | +$77.7K |
2023 Q3
5 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2024 Portfolio in Review
As of Q4 2024, JP Morgan Chase held 7,917 positions worth $1.34T, up 2.1% from $1.32T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q4 2024 filing shows 509 new, 3,351 increased, 2,465 reduced and 522 closed positions. Its largest new stake was Primo Brands: 3,989,501 shares worth $123M. The largest sale was Eli Lilly, an estimated $2.77B.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 24% a quarter earlier, followed by Technology and Financials.
- JP Morgan Chase's largest Q4 2024 buy was Primo Brands: 3,989,501 shares worth $123M.
- JP Morgan Chase added most to Broadcom in Q4 2024, an estimated $3.21B increase.
- JP Morgan Chase's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $2.77B.
- JP Morgan Chase fully exited Stericycle Inc in Q4 2024, selling an estimated $183M.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.34T portfolio in Q4 2024.
- JP Morgan Chase opened 509 new positions and closed 522 in Q4 2024.
- JP Morgan Chase's portfolio value rose 2.1% quarter-over-quarter to $1.34T.
Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.